Pfizer
PFE
2,526 hedge funds and large institutions have $157B invested in Pfizer in 2019 Q4 according to their latest regulatory filings, with 311 funds opening new positions, 1,008 increasing their positions, 971 reducing their positions, and 77 closing their positions.
304% more first-time investments, than exits
New positions opened: 311 | Existing positions closed: 77
32% more funds holding in top 10
Funds holding in top 10: 81 → 107 (+26)
10% more capital invested
Capital invested by funds: $142B → $157B (+$14.3B)
9% more funds holding
Funds holding: 2,324 → 2,526 (+202)
4% more repeat investments, than reductions
Existing positions increased: 1,008 | Existing positions reduced: 971
0.51% more ownership
Funds ownership: 71.68% → 72.19% (+0.51%)
16% less call options, than puts
Call options by funds: $1.19B | Put options by funds: $1.41B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$835M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$713M |
| 3 |
Renaissance Technologies
New York
|
+$331M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$269M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$231M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.43B |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$381M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$188M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$188M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$121M |
PFE Hedge Fund Activity: Q4 2019 in Review
2,526 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2019, worth a combined $157B — up 10% from $142B a quarter earlier.
Buyers outnumbered sellers: 311 funds opened new PFE positions and 77 closed out — a net gain of 234 holders — while 1,008 added to existing stakes and 971 trimmed.
The largest buyer was Capital World Investors, adding an estimated $835M. The largest seller was JP Morgan Chase, cutting an estimated $1.43B.
- 2,526 institutional investors held Pfizer (PFE) as of Q4 2019, up from 2,324 in Q3 2019.
- Funds reported $157B of Pfizer stock for Q4 2019, up 10% quarter-over-quarter.
- 311 funds opened new Pfizer positions in Q4 2019 and 77 closed out, a net change of +234 holders.
- The largest Pfizer buyer in Q4 2019 was Capital World Investors, an estimated $835M added.
- The largest Pfizer seller in Q4 2019 was JP Morgan Chase, an estimated $1.43B sold.
Based on aggregated 13F filings for Q4 2019.